Fondaparinux (trade name Arixtra) is an anticoagulant medication chemically
related to low molecular weight heparins. It is marketed by GlaxoSmithKline.
Medscape - Indication-specific dosing for Arixtra (fondaparinux), frequency-
based adverse effects, comprehensive interactions, contraindications, pregnancy
ARIXTRA® (fondaparinux sodium) Injection is a sterile solution containing
fondaparinux sodium. It is a synthetic and specific inhibitor of activated Factor X (
Learn about clinical pharmacology for the drug Arixtra (Fondaparinux Sodium).
Fondaparinux is used to treat serious blood clots in the legs and/or lungs. It is
usually used with another "blood thinner" medication (warfarin). If untreated,
Oct 14, 2016 ... The first fondaparinux administration should be given not earlier than 6 hours
following surgical closure. The injection should not be given ...
Mar 15, 2014 ... Fondaparinux Injection: learn about side effects, dosage, special precautions,
and more on MedlinePlus.
May 16, 2016 ... Fondaparinux is an anticoagulant that helps prevent the formation of blood clots.
Jun 13, 2005 ... Binding of heparin/HS to ATIII has been shown to increase the anti-coagulant
activity of antithrombin III 1000-fold. Fondaparinux potentiates the ...
Expert Opin Investig Drugs. 2002 Mar;11(3):397-407. Fondaparinux: a synthetic
heparin pentasaccharide as a new antithrombotic agent. Walenga JM(1), Jeske ...